The significance of serum transforming growth factor beta 1 in detecting of gastric and colon cancers

Hepato-Gastroenterology

Volumn 54, Issue 77, 2007, Pages 1472-1476

  Çoban, Sahin ^a,f   Yüksel, Osman ^b   Koçkar, Muhammed Cem ^c   Köklü, Seyfettin ^d   Basar, Ömer ^e   Tutkak, Hüseyin ^a   Örmeci, Necati ^a  

^a ANKARA UNIVERSITY   (Turkey)

^b ANKARA NUMUNE HOSPITAL   (Turkey)

^c SULEYMAN DEMIREL UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^d KASTAMONU UNIVERSITY   (Turkey)

^e TURKIYE YUKSEK IHTISAS HOSPITAL   (Turkey)

^f NONE   (Turkey)

Author keywords

Cancer; Gastrointestinal tract; TGF 1

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; TRANSFORMING GROWTH FACTOR BETA1; TUMOR MARKER;

ADULT; ARTICLE; CANCER INVASION; CELL DIFFERENTIATION; COLON CANCER; CONTROLLED STUDY; DIGESTIVE SYSTEM CANCER; FEMALE; HISTOPATHOLOGY; HUMAN; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENSITIVITY AND SPECIFICITY; STOMACH CANCER;

COLONIC NEOPLASMS; FEMALE; HUMANS; MALE; MIDDLE AGED; SENSITIVITY AND SPECIFICITY; STOMACH NEOPLASMS; TRANSFORMING GROWTH FACTOR BETA1; TUMOR MARKERS, BIOLOGICAL;

EID: 34547628509     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Waisberg J, Contim-Neto L, Oliveria MSL, Matheus CO, Nagashima CA, Goffi FS: Determination of carcinoembryonic antigen levels in peripheral and draining blood in patients with colorectal carcinoma. Arq Gastroenterol 2004; 41:88-92.
2. Fernandes LC, Kim SB, Delcio M: Cytokeratins and carcinoembryonic antigen in diagnosis, staging and prognosis of colorectal adenocarcinoma. World J Gastroenterol 2005; 11:645-648.
3. Yamao T, Kai S, Kazami A, Koizumi K, Handa T, Takemoto N, Maruyama M: Tumor markers CEA, CA19-9 and CA125 in monitoring of response to systemic chemotherapy in patients with advanced gastric cancer. Jpn J Clin Oncol 1999; 29:550-555.
4. Dimberg J, Hugander A, Sirsjo A: Decreased levels of precursor transforming growth factor beta 1 in human colorectal cancer. Int J Mol Med 2001; 7:597-601.
5. Miyazono K, Suzuki H, Imamura T: Regulation of TGB-β signaling and its roles in progression of tumors. Cancer Sci 2003; 94:230-234.
6. Weiser R: The transforming growth factor-β signaling pathway in tumorigenesis. Curr Opin Oncol 2001; 13:70-77.
7. Lagadec P, Raynal S, Lieubeau B, Onier N, Arnould L, Saint-Giorgio V, Lawrence DA, Jeannin JF: Evidence of control of nitric oxide synthesis by intracellular transforming growth factor-β1 in tumor cells. Am J Pathol 1999; 154:1867-1876.
8. Natsugoe S, Xiangming C, Matsumoto M, Okumura H, Nakashima S, Sakita H, Ishigami S, Baba M, Takao S, Aikou T: Smad4 and transforming growth factor β1 expression in patients with squamous cell carcinoma of the esophagus. Clin Cancer Res 2002; 8:1838-1842.
9. Ye SC, Foster JM, Li W, Liang J, Zborowska E, Venkateswarlu S, Gong J, Brattain MG, Willson JK: Contextual effects of transforming growth factor β on the tumorigenicity of human colon carcinoma cells. Cancer Res 1999; 59:4725-4731.
10. Gomella LG, Sargent ER, Wade TP, Anglard P, Linehan WM, Kasid A: Expression of transforming growth factor-α in normal adult kidney and enhanced expression of transforming growth factor-α and β1 in renal cell carcinoma. Cancer Res 1989; 49:6972-6975.
11. Shirai Y, Kawata S, Tamura S, Ito N, Tsushima H, Takaishi K, Kiso S, Matsuzawa YI: Plasma transforming growth factor-β in patients with hepatocellular carcinoma. Cancer 1994; 73:2275-2279.
12. Dalal BI, Keown PA, Greenberg AH: Immunocytochemical localization of secreted transforming growth factor-β1 to the advancing edges of primary tumors and to lymph node metastases of human mammary carcinoma. Am J Pathol 1993; 143:381-389.
13. Tsushima H, Kawata S, Tamura S, Ito N, Shirai Y, Kýso S, Imai Y, Shimomukai H, Nomura Y, Matsuda Y, Matsuzawa Y: High level of transforming growth factor β1 in patients with colorectal cancer: Association with disease progression. Gastroenterology 1996; 110:375-382.
14. Narai S, Watanabe M, Hasegawa H, Nishibori H, Endo T, Kubota T, Kitajima M: Significance of transforming growth factor β1 as a new tumor marker for colorectal cancer. Int J Cancer 2002; 97:508-511.
15. Maehara BY, Kakeji Y, Kabashima A, Emi Y, Watanebe A, Akazawa K, Baba H, Kohnoe S, Sugimachi K: Role of transforming growth factor β1 in invasion and metastasis in gastric carcinoma. J Clin Oncol 1999; 17:607-614.
16. Massague J: TGF-β signal transduction. Ann Rev Biochem 1998; 67:753-791.
17. Fukuchi M, Fukai Y, Masuda N, Miyazaki T, Nakajima M, Sohda M, Manda R, Tsukada K, Kato H, Kuwano H: High-level expression of the smad ubiquitin ligase smurf2 correlates with poor prognosis in patients with esophageal squamous cell carcinoma. Cancer Res 2002; 62:7162-7165.
18. Oft M, Heider KH, Beug H: TGF beta signaling is necessary for carcinoma cell invasiveness and metastasis. Curr Biol 1998; 8:1243-1252.
19. Nakamura M, Katano M, Kuwahara A, Fujimoto K, Miyazaki K, Morisaki T, Mori M: Transforming growth factor beta 1 (TGF-beta 1) is a preoperative prognostic indicator in advanced gastric carcinoma. Br J Cancer 1998; 78:1373-1378.
20. Fukuchi M, Miyazaki T, Fukai Y, Nakajima M, Sohda M, Masuda N, Manda R, Tsukada K, Katao H, Kuwano H: Plasma level of transforming growth factor β1 measured from the azygos vein predicts prognosis in patients with esophageal cancer. Clin Cancer Res 2004: 10:2738-2741.
21. Shim KS, Kim KH, Han WS, Park EB: Elevated serum levels of transforming growth factor-beta1 in patients with colorectal carcinoma: its association with tumor progression and its significant decrease after curative surgical resection. Cancer 1999; 85:554-561.
22. Park YE, Choi YH, Lee WY, Choi KC: Transforming growth factor β1 expression in gastric carcinoma. J Korean Med Sci 1997; 12:215-220.
23. Wakefield LM, Letterio JJ, Chen T, Danielpour D, Allison RS, Pai LH, et al: Transforming growth factor β1 circulates in normal human plasma and is unchanged in advanced metastatic breast cancer. Clin Cancer Res 1995; 1:129-136.
24. Ueki N, Ohkawa T, Yokoyama Y, Maeda J, Kawai Y, Ikeda T, Amuro Y, Hada T, Higoshino KI: Potentiation of metastatic capacity by transforming growth factor-β1 gene transfection. Jpn J Cancer Res 1993; 84:589-593.
25. Xiong B, Gong LL, Zhang F,Hu MB, Yuan HY: TGF-β1 expression and angiogenesis in colorectal cancer tissue. World J Gastronterol 2002; 8:496-498.
26. Park D 2nd, Son HJ, Song SY, Choe WH, Lim YJ, Park SJ, Kim JJ, Kim YH, Rhee PL, Paik SW, Rhee JC, Choi KW: Role of TGF-beta 1 and TGF-beta type II receptor in gastric cancer. Korean J Intern Med 2002; 17:160-166.
27. Saito H, Tsujitani S, Oka S, Kondo A, Ikeguchi M, Maeta M, Kaibara N: An elevated serum level of transforming growth factor-beta1 significantly correlated with lymph node metastasis and poor prognosis in patients with gastric carcinoma. Anticancer Res 2000; 20:4489-4493.
28. Guzinska- Ustymowicz K, Kemona A: Transforming growth factor beta can be parameter of aggressiveness of pT1 colorectal. World J Gastroenterol 2005; 11:1193-1195.
29. Choi YE, Choi KC, Park YE: Relationship of transforming growth factor β1 to angiogenesis in gastric carcinoma. J Korean Med Sci 1997; 12:427-432.
30. Forenes NM, Tanaka M: CEA and CA 19-9 as a prognostic indexes in colorectal cancer. Hepatogastroenterology 1999; 46:905-908.
31. Carpelan-Holmstrom MA, Haglund CH, Roberts PJ: Differences in serum tumor markers between colon and rectal cancer. Comparison of CA 242 and carcinoembryonic antigen. Dis Colon Rectum 1996; 39:799-805.
32. Fernandez-Fernandez L, Tejero E, Tieso A: Significance of CA 72-4 in colorectal carcinoma. Comparison with CEA and CA 19-9. Eur J Surg Oncol 1995; 21:388-390.
33. Carpelan-Holmstrom M, Haglund C, Kuusela P, Jarvinen H, Roberts PJ: Preoperative serum levels of CEA and CA 242 in colorectal cancer. Br J cancer 1995; 71:868-872.
34. Hall NR, Finan PJ, Stephenson BM, Purves DA, Cooper EH: The role of CA 242 and CEA in surveillance following curative resection for colorectal cancer. Br J Cancer 1994; 70:549-553.
35. Mattar R, Alvares de Andrade CR, DiFavero GM, Gama-Rodrigues JJ, Laudanna AA: Preoperative serum levels of CA 72-4, CEA, CA19-9 and alpha-fetoprotein in patients with gastric cancer. Rev Hosp Clin Fac Med Sao Paulo 2002; 57:89-92.
36. Victorzon M, Hanglud C, Lundin J, Roberts PJ: A prognostic value of CA19-9 but not of CEA in patient with gastric cancer. Eur J Surg Oncol 1995; 21:379-384.
37. Ebert MP, Yu J, Miehlke S, Fei G, Lendeckel U, Ridwelski K, Stolte M, Bayerdorffer E, Malfertheiner P: Expression of transforming growth factor beta-1 in gastric cancer and in the gastric mucosa of first-degree relatives of patients with gastric cancer. Br J Cancer 2000; 82:1795-1800.
38. Saito H, Tsujitani S, Oka S,Kondo A, Ikeguchi M, Maeta M, Kaibara N: The expression of transforming growth factor-betal is significantly correlated with the expression of vascular endothelial growth factor and poor prognosis of patients with advanced gastric carcinoma. Cancer 1999; 86:1455-1462.